- Member Since
- Sep 2, 2024
- Posts
- 876
- Likes Received
- 6,148

geoguy78 said:I'm definitely interested in both Maz and Survo. Keep us posted on this one. Innovent has two New Drug Applications submitted with the Chinese authorities currently, the Phase 3 studies there are looking impressive.
It's been approved in China for both obesity and diabetes. People in China can purchase it now if they're able to pay the slightly over 400 USD that it costs.
I didn't realize this until I started reading about mazdutide, but China actually has a big diabetes problem. Many Asian people get fatty liver at far lower BMIs than others.
Semaglutide goes generic in China in 2026. (It also becomes generic in Canada that same year because some idiot at Novo forgot to pay the approximately 185 USD fee to renew the Canadian patent.) Once sema goes generic in China, I bet it becomes a blockbuster drug for both weight and diabetes.

